image description

Tag: belimumab

Research Shows Benefit to Starting Belimumab Sooner Rather Than Later

April 16, 2020 Treating people with lupus earlier with belimumab (Benlysta) may work better than as a last option according to a study just published in the well-respected journal Arthritis & Rheumatology  Researchers in Italy analyzed data from 466 people with lupus at 24 centers in Italy who were receiving belimumab intravenously.  They looked at […] Read More

LRA Shares Excitement For What’s Ahead in Lupus Nephritis

January 16, 2020 Up to half of people with lupus will have lupus nephritis – damage to the kidneys that affects the ability to clear the body of wastes and toxins. In 2020, we expect to see significant progress in new drug development for lupus and lupus nephritis in particular with submissions for FDA approval in […] Read More

LRA Celebrates Major Research Breakthroughs in 2019

January 7, 2020 2019 was a phenomenal, breakthrough year for lupus research on both the clinical development and basic science fronts. The Lupus Research Alliance (LRA) is incredibly proud that every new discovery leading to a brand new medicine for lupus had its origin in work funded by LRA years ago. The past 12 months delivered many […] Read More

New Phase 3 Study Shows Positive Results for Benlysta® in Lupus Nephritis

December 17, 2019 The Lupus Research Alliance is thrilled to share exciting news from GSK that Benlysta (belimumab) demonstrated positive clinical trial results in treating lupus nephritis (LN), a common complication of lupus causing inflammation of the kidneys that can result in end-stage kidney disease. Called BLISS-LN, this Phase 3 trial is the largest one […] Read More

New Study Shows Benlysta Alters B Cells in People with Lupus

August 21, 2019 Newly published research found that belimumab (Benlysta®) effectively reduced the number of B cells, a type of white blood cell that makes antibodies.  According to the prescribing information, belimumab is “a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of patients aged 5 years and older with active, autoantibody positive, systemic lupus […] Read More

Study Shows Need for Greater Awareness of Biologics for Lupus

August 19, 2019 A new study led by Dr. S. Sam Lim of Emory University found a need for more awareness of biologic therapies among both black and white people with lupus.  Biologics are medicines that come from living cells to prevent, treat and cure human diseases, and are designed to have specific effects on […] Read More

Updates in Lupus Clinical Research from the LUPUS 2019 Meeting

April 11, 2019 The Lupus Research Alliance is pleased to share the results from four clinical trials presented at LUPUS 2019.  These studies continue to push our way forward toward new and improved treatments to help the lupus community. There’s a Silver Lining in New Belimumab Results Jim Oates, MD, Medical University of South Carolina, […] Read More

Benlysta Approved for Children 5-Years and Up

April 26, 2019 We are very pleased to share news from GlaxoSmithKline (GSK) that intravenous Benlysta (belimumab) was approved by the U.S. Food and Drug Administration to treat children with lupus who are five years old or above. The approval was based on data from the ‘PLUTO’ study testing over one year the effectiveness and […] Read More

New Guidelines for Lupus Treatment From EULAR

April 10, 2019 New recommendations for treating systemic lupus erythematosus were just issued by EULAR – the European League Against Rheumatism (EULAR) and published in Annals of the Rheumatic Diseases . A group of researchers from 29 medical centers across Europe reviewed all the current literature on lupus treatment to formulate questions, elicit expert opinions […] Read More
Stay informed about events, research developments, and ways you can help. Sign up for updates